GPCR Structure-Based Drug Discovery: Identification and Structural Insights into Selective and Non-selective Orexin-1 & 2 Antagonists for the Treatment of Insomnia and Addiction DisordersTuesday, 18 February 2014 at 10:45 Add to Calendar ▼2014-02-18 10:45:002014-02-18 11:45:00Europe/LondonGPCR Structure-Based Drug Discovery: Identification and Structural Insights into Selective and Non-selective Orexin-1 and 2 Antagonists for the Treatment of Insomnia and Addiction DisordersDiscovery Chemistry Congress in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com Through the generation and utilisation of OX1 and OX2 StaRs® we have been able to rapidly progress a dual orexin receptor antagonist (DORA) series to a pre-clinical candidate. The structures have also highlighted the unique and differing basis for varied Orexin chemotypes’ selectivity. |